Formulation study for lansoprazole fast-disintegrating tablet. III. Design of rapidly disintegrating tablets

被引:49
作者
Shimizu, T [1 ]
Sugaya, M [1 ]
Nakano, Y [1 ]
Izutsu, D [1 ]
Mizukami, Y [1 ]
Okochi, K [1 ]
Tabata, T [1 ]
Hamaguchi, N [1 ]
Igari, Y [1 ]
机构
[1] Takeda Chem Ind Ltd, Div Pharmaceut Prod, Pharmaceut Dev Labs, Yodogawa Ku, Osaka 532868, Japan
关键词
rapidly disintegrating tablets; roughness; L-HPC; compression force; dissolution;
D O I
10.1248/cpb.51.1121
中图分类号
R914 [药物化学];
学科分类号
100701 [药物化学];
摘要
Lansoprazole fast-disintegrating tablets (LFDT) are a patient-friendly formulation that rapidly disintegrates in the mouth. LFDT consist of enteric-coated microgranules (mean particle size, approximately 300 mum) and inactive granules. In the design of the inactive granules, mannitol was used as a basic excipient. Microcrystalline cellulose, low-substituted hydroxypropyl cellulose (L-HPC), and crospovidone were used as binders and disintegrants. A new grade of L-HPC (L-HPC-33), with a hydroxypropoxy group content of 5.0-6.9%, was developed and it has no rough texture due to a decrease in water absorption. It was clarified that L-HPC-33 could be useful as a binder and disintegrant in rapidly disintegrating tablets. LFDT contain enteric-coated microgranules in tablet form. The enteric-coated microgranule content in LFDT affect qualities such as tensile strength, disintegration time in the mouth, and dissolution behavior in the acid stage and in the buffer stage of LFDT. The 47.4% content of the enteric-coated microgranules was selected to give sufficient tensile strength (not less than 30 N/cm(2)), rapid disintegration time in the mouth (not more than 30 s), and dissolution behavior in the acid stage and buffer stage similar to current lansoprazole capsules. Compression force affected the tensile strength and the disintegration time in the mouth, but did not affect the dissolution behavior in the acid and buffer stages.
引用
收藏
页码:1121 / 1127
页数:7
相关论文
共 31 条
[1]
Allen L.V., 1998, US Patent, Patent No. [5807576, US5807576]
[2]
ALLEN LV, 1999, Patent No. 5587180
[3]
THE STRENGTH AND COMPACTION OF MILLISPHERES - THE DESIGN OF A CONTROLLED-RELEASE DRUG-DELIVERY SYSTEM FOR IBUPROFEN IN THE FORM OF A TABLET COMPRISING COMPACTED POLYMER-COATED MILLISPHERES [J].
AULTON, ME ;
DYER, AM ;
KHAN, KA .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1994, 20 (20) :3069-3104
[4]
COATED PELLETIZED DOSAGE FORM - EFFECT OF COMPACTION ON DRUG RELEASE [J].
BECHARD, SR ;
LEROUX, JC .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1992, 18 (18) :1927-1944
[5]
Compression of enteric-coated pellets to disintegrating tablets [J].
Beckert, TE ;
Lehmann, K ;
Schmidt, PC .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 143 (01) :13-23
[6]
Bi YX, 1996, CHEM PHARM BULL, V44, P2121
[7]
CELIK M, 1994, DRUG DEV IND PHARM, V20, P3151
[8]
Formulation and production of rapidly disintegrating tablets by lyophilisation using hydrochlorothiazide as a model drug [J].
Corveleyn, S ;
Remon, JP .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1997, 152 (02) :215-225
[9]
Bioavailability of hydrochlorothiazide: Conventional versus freeze-dried tablets [J].
Corveleyn, S ;
Remon, JP .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1998, 173 (1-2) :149-155
[10]
Stability of freeze-dried tablets at different relative humidities [J].
Corveleyn, S ;
Remon, JP .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1999, 25 (09) :1005-1013